Search
Abiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalAbiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis … It is used to treat metastatic castration-resistant prostate cancer, hormone-sensitive high-risk metastatic prostate cancer.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, 17-(3-Pyridyl)androsta-5,16-dien-3beta-olInterferon beta-1a
go.drugbank.com/drugs/DB00060ApprovedInvestigationalHuman interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced.
Categories: interferon beta-1a, Interferon Type ISynonyms: Interferon beta 1-a, IFN β-1aValdecoxib
go.drugbank.com/drugs/DB00580ApprovedWithdrawnValdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Categories: Heterocyclic Compounds, 1-Ring, COX-2 InhibitorsProducts: BEXTRA ® 10 MG TABLETAS RECUBIERTAS, BEXTRA®20 MG TABLETAS RECUBIERTASCorifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalThis means that it is made by cells into which a DNA has been introduced that makes them able to produce corifollitropin alfa [L2270]. … Corifollitropin alfa, also known as _Elonva_ is used in women undergoing fertility treatment to stimulate the development of more than one mature egg (oocyte) at a time in the ovaries.
Products: ELONVA 150 MCG/0,5 ML ENJEKSIYONLUK COZELTI, 1 ADET, ELONVA 100 MCG/0,5 ML ENJEKSİYONLUK ÇÖZELTİ, 1 ADETHyperkeratosis follicularis et parafollicularis
go.drugbank.com/conditions/DBCOND0020027Drugs: Salicylic acidSynonyms: Hyperkeratosis follicularis et parafollicularis, Keratosis follicularis et parafollicularis in cutem penetransDuloxetine
go.drugbank.com/drugs/DB00476ApprovedInvestigationalDuloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.
Synonyms: (3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine, (S)-duloxetineCategories: Heterocyclic Compounds, 1-Ring, P-glycoprotein inhibitorsTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigationalCTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).
Categories: CTLA-4-directed Blocking AntibodyProducts: Imjudo 300 mg/15 ml İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 adet, Imjudo 25 mg/1.25 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 adetNadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922] … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.
Mixtures: CORGARETIC (NADOLOL/ BENDROFLUMETIAZIDA) 80/5 MG, Corzide Tab W Nadolol 80mgCategories: MATE 1 Substrates, MATE 2 SubstratesFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigational[A183176,L8090] It is an anilinopyrimidine derivative.[A183188] Fedratinib was granted FDA approval on August 16, 2019.[L8090] … Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.
Categories: MATE 1 Inhibitors, Heterocyclic Compounds, 1-RingProducts: Inrebic 100 mg capsules, Inrebic 100 mg Sert Kapsül, 120 ADETAtezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigationalAtezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. … [L7489] Atezolizumab was granted FDA approval on 18 October 2016.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: TECENTRIQ 1200 MG / 20 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, TECENTRIQ CONCENTRATE FOR SOLUTION FOR INFUSION 1200 MG/ 20 ML